<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Gilead Sciences Inc — News on 6ix</title>
    <link>https://6ix.com/company/gilead-sciences-inc</link>
    <description>Latest news and press releases for Gilead Sciences Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 12:30:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/gilead-sciences-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683577a378dffbe2df0f7b96.webp</url>
      <title>Gilead Sciences Inc</title>
      <link>https://6ix.com/company/gilead-sciences-inc</link>
    </image>
    <item>
      <title>U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment of Bictegravir Plus Lenacapavir</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/us-fda-grants-priority-review-of-new-drug-application-for-gileads-once-daily-hiv-treatment-of-bictegravir-plus-lenacapavir</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/us-fda-grants-priority-review-of-new-drug-application-for-gileads-once-daily-hiv-treatment-of-bictegravir-plus-lenacapavir</guid>
      <pubDate>Wed, 29 Apr 2026 12:30:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., April 29, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) – an investigational, once-daily single-tablet combination regimen for the treatment of HIV in adults who are virologically suppressed. The FDA has granted priority review of the application and assigned a Prescription Drug User Fee Act (PDUFA) action date of Augus</description>
    </item>
    <item>
      <title>Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel</guid>
      <pubDate>Tue, 28 Apr 2026 12:45:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., April 28, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its previously announced acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing.</description>
    </item>
    <item>
      <title>Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-release-first-quarter-2026-financial-results-on-thursday-may-7-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-release-first-quarter-2026-financial-results-on-thursday-may-7-2026</guid>
      <pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2026 financial results and guidance will</description>
    </item>
    <item>
      <title>Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-receives-all-required-regulatory-approvals-for-the-acquisition-of-arcellx-and-extends-tender-offer</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-receives-all-required-regulatory-approvals-for-the-acquisition-of-arcellx-and-extends-tender-offer</guid>
      <pubDate>Fri, 17 Apr 2026 12:30:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., April 17, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.</description>
    </item>
    <item>
      <title>PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir for HIV Prevention to Further Expand Access</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/pepfar-and-the-global-fund-make-additional-investment-in-gileads-lenacapavir-for-hiv-prevention-to-further-expand-access</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/pepfar-and-the-global-fund-make-additional-investment-in-gileads-lenacapavir-for-hiv-prevention-to-further-expand-access</guid>
      <pubDate>Tue, 14 Apr 2026 16:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif., April 14, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. State Department, the United States President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead’s twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028.</description>
    </item>
    <item>
      <title>Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&amp;D Through RWE</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/tempus-announces-strategic-collaboration-with-gilead-to-advance-oncology-randd-through-rwe-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/tempus-announces-strategic-collaboration-with-gilead-to-advance-oncology-randd-through-rwe-1</guid>
      <pubDate>Thu, 09 Apr 2026 12:30:00 GMT</pubDate>
      <description>CHICAGO, April 09, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (Nasdaq: GILD) aimed at building and advancing Gilead’s oncology pipeline.</description>
    </item>
    <item>
      <title>Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/cartography-biosciences-advances-strategic-oncology-collaboration-with-gileads-first-option-target-exercise</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/cartography-biosciences-advances-strategic-oncology-collaboration-with-gileads-first-option-target-exercise</guid>
      <pubDate>Thu, 09 Apr 2026 11:30:00 GMT</pubDate>
      <description>SOUTH SAN FRANCISCO, Calif., April 09, 2026--Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that Gilead Sciences, Inc. has exercised the first of its options to exclusively license a novel oncology target discovered and validated through Cartography’s proprietary ATLAS and SUMMIT platforms arising out of the parties’ collaboration.</description>
    </item>
    <item>
      <title>Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-to-acquire-tubulis-adding-potentially-best-in-class-antibody-drug-conjugate-and-next-generation-platform-to-further-strengthen-oncology-pipeline</guid>
      <pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
      <description>– Acquisition Adds TUB-040, a NaPi2b Targeting ADC for Ovarian Cancer and other Solid Tumors, to Gilead Pipeline – – Industry Leading ADC Platform That</description>
    </item>
    <item>
      <title>Gilead Extends Tender Offer to Acquire Arcellx</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-extends-tender-offer-to-acquire-arcellx-6</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-extends-tender-offer-to-acquire-arcellx-6</guid>
      <pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding</description>
    </item>
    <item>
      <title>Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-1</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases-1</guid>
      <pubDate>Tue, 31 Mar 2026 05:30:00 GMT</pubDate>
      <description>New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class &amp; best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium</description>
    </item>
    <item>
      <title>Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-acquire-ouro-medicines-to-advance-first-in-class-t-cell-engager-program-for-autoimmune-diseases</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>-- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio -- -- Gilead</description>
    </item>
    <item>
      <title>Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-foundation-awards-dollar12-million-to-empower-community-health-workers-and-expand-hiv-prevention-initiatives-across-14-states-and-the-district-of-columbia</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-foundation-awards-dollar12-million-to-empower-community-health-workers-and-expand-hiv-prevention-initiatives-across-14-states-and-the-district-of-columbia</guid>
      <pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
      <description>– Grants to Strengthen Prevention Models and Local Systems of Care Nationwide – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Foundation today announced a</description>
    </item>
    <item>
      <title>Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gileads-single-tablet-regimen-of-bictegravir-and-lenacapavir-maintained-virological-suppression-in-people-with-hiv-who-switched-antiretroviral-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gileads-single-tablet-regimen-of-bictegravir-and-lenacapavir-maintained-virological-suppression-in-people-with-hiv-who-switched-antiretroviral-therapy</guid>
      <pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
      <description>– Novel Investigational Combination Pairs Bictegravir, a Global Guideline-Recommended Integrase Strand Transfer Inhibitor with a High Barrier to Resistance</description>
    </item>
    <item>
      <title>Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel</guid>
      <pubDate>Mon, 23 Feb 2026 11:01:00 GMT</pubDate>
      <description>FOSTER CITY, Calif. &amp; REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur</description>
    </item>
    <item>
      <title>Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel-2</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-to-acquire-arcellx-to-maximize-long-term-potential-of-anito-cel-2</guid>
      <pubDate>Mon, 23 Feb 2026 11:01:00 GMT</pubDate>
      <description>FOSTER CITY, Calif. &amp; REDWOOD CITY, Calif., February 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incur</description>
    </item>
    <item>
      <title>Stem Cell and Regenerative Therapy Markets, 2022-2025 &amp; Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/stem-cell-and-regenerative-therapy-markets-2022-2025-and-forecast-to-2030-featuring-profiles-of-leading-companies-gilead-sciences-novartis-bristol-myers-squibb-organogenesis-mimedx-group-and-more</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/stem-cell-and-regenerative-therapy-markets-2022-2025-and-forecast-to-2030-featuring-profiles-of-leading-companies-gilead-sciences-novartis-bristol-myers-squibb-organogenesis-mimedx-group-and-more</guid>
      <pubDate>Fri, 20 Feb 2026 12:21:00 GMT</pubDate>
      <description>Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic production while reducing costs, fueling market growth and adoption Stem Cell and Regenerative Therapy Market Stem Cell and Regenerative Therapy Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The &quot;Stem Cell and Regenerative Therapy: Global Markets&quot; has been added to ResearchAndMarkets.com&apos;s offering. The global stem cell and regenerative therapy market is poised for subs</description>
    </item>
    <item>
      <title>Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-to-present-new-hiv-treatment-and-prevention-data-at-croi-2026-with-a-focus-on-expanding-options</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-to-present-new-hiv-treatment-and-prevention-data-at-croi-2026-with-a-focus-on-expanding-options</guid>
      <pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
      <description>– Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from</description>
    </item>
    <item>
      <title>Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-announces-38-percent-increase-in-first-quarter-2026-dividend</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-announces-38-percent-increase-in-first-quarter-2026-dividend</guid>
      <pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
      <description>FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of</description>
    </item>
    <item>
      <title>Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/gilead-sciences-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
      <pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
      <description>Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7% Year-Over-Year to $14.3 billion</description>
    </item>
    <item>
      <title>FDA Approves Label Update for Kite’s Yescarta® for Relapsed/Refractory Primary Central Nervous System Lymphoma</title>
      <link>https://6ix.com/company/gilead-sciences-inc/news/fda-approves-label-update-for-kites-yescartar-for-relapsedrefractory-primary-central-nervous-system-lymphoma</link>
      <guid isPermaLink="true">https://6ix.com/company/gilead-sciences-inc/news/fda-approves-label-update-for-kites-yescartar-for-relapsedrefractory-primary-central-nervous-system-lymphoma</guid>
      <pubDate>Fri, 06 Feb 2026 05:00:00 GMT</pubDate>
      <description>– Limitations of Use Removed for Rare and Aggressive Form of non-Hodgkin Lymphoma Based on Manageable Safety Profile with No New Safety Signals Identified –</description>
    </item>
  </channel>
</rss>